中国癌症杂志 ›› 2017, Vol. 27 ›› Issue (10): 761-769.doi: 10.19401/j.cnki.1007-3639.2017.10.001

• 论著 • 上一篇    下一篇

HMGB1/TLR4通路参与Fibulin-5对肺癌细胞增殖和转移的抑制作用

张晓娟,王慧娟,张米娜,张国伟   

  1. 郑州大学附属肿瘤医院/ 河南省肿瘤医院肿瘤内科,河南 郑州 450008
  • 出版日期:2017-10-30 发布日期:2017-12-05
  • 通信作者: 张晓娟 E-mail:yanhansunv521@163.com

Role of HMGB1/TLR4 pathway in the process of Fibulin-5 inhibiting lung cancer cells proliferation and metastasis

ZHANG Xiaojuan, WANG Huijuan, ZHANG Mina, ZHANG Guowei   

  1. Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, Henan Province, China
  • Published:2017-10-30 Online:2017-12-05
  • Contact: ZHANG Xiaojuan E-mail: yanhansunv521@163.com

摘要: 背景与目的:Fibulin-5在肺癌组织中低表达,具有抑癌作用。高迁移率族蛋白B1(high mobility group box 1,HMGB1)在肺癌中高表达,能够促进肿瘤的侵袭转移。该研究旨在探讨Fibulin-5抑制肺癌细胞增殖和转移的分子机制。方法:该研究首先检测了肺上皮细胞和肺癌细胞中Fibulin-5和HMGB1的表达,然后利用转染试剂将Fibulin-5过表达质粒和HMGB1的siRNA转染人A549细胞。实现Fibulin-5过表达和HMGB1低表达后,采用MTT实验检测细胞增殖情况,Transwell实验检测细胞的侵袭和迁移能力。本研究采用实时荧光定量聚合酶链反应(real-time fluorescent quantitative polymerase chain reaction,RTFQ-PCR)检测A549细胞中HMGB1 mRNA表达变化,采用酶联免疫吸附剂测定实验(enzyme-linked immunosorbent assay,ELisa)检测HMGB1蛋白的分泌;采用蛋白[质]印迹法(Western blot)检测HMGB1、cyclin D1、基质金属蛋白酶(matrix metalloproteinases,MMPs)和TLR4/NF-κB通路相关蛋白的表达变化。结果:在肺癌细胞A549中,Fibulin-5低表达,HMGB1高表达。过表达Fibulin-5和低表达HMGB1后,HMGB1、cyclin D1、MMP2、MMP7和MMP9的表达均明显降低,A549细胞的增殖、侵袭和迁移能力明显减弱(P<0.05);此外,过表达Fibulin-5下调了TLR4、MyD88、p-p65的表达,上调了IκBα的表达(P<0.05)。结论:Fibulin-5可能是通过抑制HMGB1的表达以及其下游的TLR4/NF-κB通路,抑制肺癌细胞的增殖、侵袭和迁移的过程。

关键词: Fibulin-5, 高迁移率族蛋白B1, TLR4/NF-κB通路, 肺癌, 侵袭, 迁移

Abstract:

Background and purpose: The expression of Fibulin-5, a tumor suppressor, is reduced in lung cancer tissues. High mobility group box 1 (HMGB1), overexpressed in lung cancer, can promote the invasion and metastasis of the tumor. This study aimed to investigate the molecular mechanism of Fibulin-5 inhibiting the proliferation and metastasis of lung cancer cells. Method: Firstly the expressions of Fibulin-5 and HMGB1 in lung epithelial cells and lung cancer cells were detected. Then transfection reagents were used to transfect Fibulin-5 plasmid and HMGB1 siRNA into A549 cells, which achieved Fibulin-5 overexpression and HMGB1 down-regulation. MTT was used to detect the cell proliferation. Transwell was used to examine the ability of cell invasion and migration. HMGB1 mRNA expression was detected by real-time fluorescence quantitative polymerase chain reaction (RTFQ-PCR). The secretion of HMGB1 protein was analyzed by enzyme-linked immunosorbent assay (ELISA). Western blot was used to detect the levels of HMGB1, cyclin D1, matrix metalloproteinases (MMPs), and TLR4/NF-κB pathway related proteins. Results: In A549 cell, Fibulin-5 expression was down-regulated and HMGB1 expression was up-regulated. After overexpression of Fibulin-5 or knockdown of HMGB1 in A549 cells, the levels of HMGB1, cyclin D1, MMP2, MMP7 and MMP9 were significantly reduced; the abilities of lung cancer cell proliferation, invasion and migration were notably suppressed (P<0.05). In addition, Fibulin-5 overexpression decreased the protein expressions of TLR4, MyD88, p-p65, increased the expression of IκBα (P<0.05). Conclusion: Fibulin-5 may inhibit lung cancer cell proliferation, invasion and migration via inhibiting the expression of HMGB1 and its downstream TLR4/NF-κB pathway.

Key words: Fibulin 5, High mobility group box 1, TLR4/NF-κB pathway, Lung cancer, Invasion, Migration